Tackling the dysregulated immune-checkpoints in classical Hodgkin lymphoma: bidirectional regulations between the microenvironment and Hodgkin/Reed-Sternberg cells
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Tackling the dysregulated immune-checkpoints in classical Hodgkin lymphoma: bidirectional regulations between the microenvironment and Hodgkin/Reed-Sternberg cells
Authors
Keywords
-
Journal
Frontiers in Oncology
Volume 13, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2023-05-24
DOI
10.3389/fonc.2023.1203470
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- An updated portrait of monocyte-macrophages in classical Hodgkin lymphoma
- (2023) Isacco Ferrarini et al. Frontiers in Oncology
- Response-adapted anti-PD1 based salvage therapy for Hodgkin lymphoma with nivolumab +/- ICE (NICE)
- (2022) Matthew G. Mei et al. BLOOD
- The International Consensus Classification of Mature Lymphoid Neoplasms: A Report from the Clinical Advisory Committee
- (2022) Elias Campo et al. BLOOD
- Chemotherapy after PD ‐1 inhibitors in relapsed/refractory Hodgkin lymphoma: Outcomes and clonal evolution dynamics
- (2022) Eleonora Calabretta et al. BRITISH JOURNAL OF HAEMATOLOGY
- The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms
- (2022) Rita Alaggio et al. LEUKEMIA
- Hodgkin lymphoma: 2023 update on diagnosis, risk‐stratification, and management
- (2022) Stephen M. Ansell AMERICAN JOURNAL OF HEMATOLOGY
- Nivolumab Plus ICE As First Salvage Therapy in High-Risk Relapsed/Refractory Hodgkin Lymphoma
- (2022) Matthew Mei et al. BLOOD
- Nivolumab and Doxorubicin, Vinblastine, and Dacarbazine in Early-Stage Unfavorable Hodgkin Lymphoma: Final Analysis of the Randomized German Hodgkin Study Group Phase II NIVAHL Trial
- (2022) Paul J. Bröckelmann et al. JOURNAL OF CLINICAL ONCOLOGY
- Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study
- (2021) John Kuruvilla et al. LANCET ONCOLOGY
- Allogeneic transplantation after PD-1 blockade for classic Hodgkin lymphoma
- (2021) Reid W. Merryman et al. LEUKEMIA
- Brentuximab vedotin in combination with nivolumab in relapsed or refractory Hodgkin lymphoma: 3-year study results
- (2021) Ranjana Advani et al. BLOOD
- Phase II Trial of Pembrolizumab Plus Gemcitabine, Vinorelbine, and Liposomal Doxorubicin as Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma
- (2021) Alison J. Moskowitz et al. JOURNAL OF CLINICAL ONCOLOGY
- Five-Year Follow-up of Keynote-087: Pembrolizumab Monotherapy in Relapsed/Refractory Classical Hodgkin Lymphoma (R/R cHL)
- (2021) Philippe Armand et al. BLOOD
- PD-L1/L2 protein levels rapidly increase on monocytes via trogocytosis from tumor cells in classical Hodgkin lymphoma
- (2020) Masaharu Kawashima et al. LEUKEMIA
- Molecular mechanism of SHP2 activation by PD-1 stimulation
- (2020) M. Marasco et al. Science Advances
- Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors
- (2020) Lorenzo Galluzzi et al. Nature Reviews Clinical Oncology
- Checkpoint Blockade Treatment May Sensitize Hodgkin Lymphoma to Subsequent Therapy
- (2020) NA Carreau et al. ONCOLOGIST
- KEYNOTE-013 4-year follow-up of pembrolizumab in classical Hodgkin lymphoma after brentuximab vedotin failure
- (2020) Philippe Armand et al. Blood Advances
- Pembrolizumab followed by AVD in untreated early unfavorable and advanced stage classical Hodgkin lymphoma
- (2020) Pamela Blair Allen et al. BLOOD
- Effectiveness of chemotherapy after anti‐PD‐1 blockade failure for relapsed and refractory Hodgkin lymphoma
- (2020) Beatrice Casadei et al. Cancer Medicine
- Tumor and microenvironment response but no cytotoxic T-cell activation in classic Hodgkin lymphoma treated with anti-PD1
- (2020) Sarah Reinke et al. BLOOD
- Expression of the Immune Checkpoint Regulators LAG-3 and TIM-3 in Classical Hodgkin Lymphoma
- (2020) Layal El Halabi et al. Clinical Lymphoma Myeloma & Leukemia
- PD-1/PD-L1 pathway: Basic biology and role in cancer immunotherapy
- (2019) Arash Salmaninejad et al. JOURNAL OF CELLULAR PHYSIOLOGY
- Clonal replacement of tumor-specific T cells following PD-1 blockade
- (2019) Kathryn E. Yost et al. NATURE MEDICINE
- The microenvironmental niche in classic Hodgkin lymphoma is enriched for CTLA-4- positive T-cells that are PD-1-negative
- (2019) Sanjay S. Patel et al. BLOOD
- Primary and acquired resistance mechanisms to immune checkpoint inhibition in Hodgkin lymphoma
- (2019) Johanna Veldman et al. CANCER TREATMENT REVIEWS
- Single-Cell Transcriptome Analysis Reveals Disease-Defining T-cell Subsets in the Tumor Microenvironment of Classic Hodgkin Lymphoma
- (2019) Tomohiro Aoki et al. Cancer Discovery
- Efficacy of chemotherapy or chemo-anti-PD-1 combination after failed anti-PD-1 therapy for relapsed and refractory Hodgkin lymphoma: A series from Lysa centers
- (2018) Cédric Rossi et al. AMERICAN JOURNAL OF HEMATOLOGY
- Pervasive mutations of JAK-STAT pathway genes in classical Hodgkin lymphoma
- (2018) Enrico Tiacci et al. BLOOD
- Mass cytometry of Hodgkin lymphoma reveals a CD4+exhausted T-effector and T-regulatory cell rich microenvironment
- (2018) Fathima Zumla Cader et al. BLOOD
- Mechanisms of resistance to immune checkpoint inhibitors
- (2018) Russell W Jenkins et al. BRITISH JOURNAL OF CANCER
- eIF2α phosphorylation is pathognomonic for immunogenic cell death
- (2018) Lucillia Bezu et al. CELL DEATH AND DIFFERENTIATION
- Human CD30+ B cells represent a unique subset related to Hodgkin lymphoma cells
- (2018) Marc A. Weniger et al. JOURNAL OF CLINICAL INVESTIGATION
- Major Histocompatibility Complex Class II and Programmed Death Ligand 1 Expression Predict Outcome After Programmed Death 1 Blockade in Classic Hodgkin Lymphoma
- (2018) Margaretha G.M. Roemer et al. JOURNAL OF CLINICAL ONCOLOGY
- Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial
- (2018) Philippe Armand et al. JOURNAL OF CLINICAL ONCOLOGY
- Increased Response Rates to Salvage Chemotherapy Administered after PD-1/PD-L1 Inhibitors in Patients with Non–Small Cell Lung Cancer
- (2018) Song Ee Park et al. Journal of Thoracic Oncology
- Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma
- (2018) Alexander M.M. Eggermont et al. NEW ENGLAND JOURNAL OF MEDICINE
- Gemcitabine alters the proteasome composition and immunopeptidome of tumour cells
- (2018) A. M. Gravett et al. OncoImmunology
- Comprehensive Genomic Profiling of Hodgkin Lymphoma Reveals Recurrently Mutated Genes and Increased Mutation Burden
- (2018) Winnie S. Liang et al. ONCOLOGIST
- Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial
- (2018) Frank Stephen Hodi et al. LANCET ONCOLOGY
- PD-1 and cancer: molecular mechanisms and polymorphisms
- (2017) Arash Salmaninejad et al. IMMUNOGENETICS
- Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma
- (2017) Robert Chen et al. JOURNAL OF CLINICAL ONCOLOGY
- Excellent response to chemotherapy post immunotherapy
- (2017) Ashish D. Dwary et al. Oncotarget
- HLA dependent immune escape mechanisms in B-cell lymphomas: Implications for immune checkpoint inhibitor therapy?
- (2017) Marcel Nijland et al. OncoImmunology
- The 2016 revision of the World Health Organization classification of lymphoid neoplasms
- (2016) S. H. Swerdlow et al. BLOOD
- Microenvironmental interactions in classical Hodgkin lymphoma and their role in promoting tumor growth, immune escape and drug resistance
- (2016) Donatella Aldinucci et al. CANCER LETTERS
- Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure
- (2016) Philippe Armand et al. JOURNAL OF CLINICAL ONCOLOGY
- PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome
- (2016) Margaretha G.M. Roemer et al. JOURNAL OF CLINICAL ONCOLOGY
- Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial
- (2016) Anas Younes et al. LANCET ONCOLOGY
- Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
- (2016) Martin Reck et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
- (2015) Julie Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
- (2015) Hossein Borghaei et al. NEW ENGLAND JOURNAL OF MEDICINE
- Overcoming T cell exhaustion in infection and cancer
- (2015) Kristen E. Pauken et al. TRENDS IN IMMUNOLOGY
- PD-1 alters T-cell metabolic reprogramming by inhibiting glycolysis and promoting lipolysis and fatty acid oxidation
- (2015) Nikolaos Patsoukis et al. Nature Communications
- Flow sorting and exome sequencing reveal the oncogenome of primary Hodgkin and Reed-Sternberg cells
- (2014) J. Reichel et al. BLOOD
- Indoleamine 2,3-dioxygenase (IDO) is frequently expressed in stromal cells of Hodgkin lymphoma and is associated with adverse clinical features: a retrospective cohort study
- (2014) Ji-Young Choe et al. BMC CANCER
- Inducible Expression of B7-H1 (PD-L1) and Its Selective Role in Tumor Site Immune Modulation
- (2014) Miguel F. Sanmamed et al. CANCER JOURNAL
- PD-1 blockade induces responses by inhibiting adaptive immune resistance
- (2014) Paul C. Tumeh et al. NATURE
- Increased plasma arginase activity in human sepsis: association with increased circulating neutrophils
- (2013) Christabelle J. Darcy et al. CLINICAL CHEMISTRY AND LABORATORY MEDICINE
- PD-1 Increases PTEN Phosphatase Activity While Decreasing PTEN Protein Stability by Inhibiting Casein Kinase 2
- (2013) Nikolaos Patsoukis et al. MOLECULAR AND CELLULAR BIOLOGY
- Tumor-associated macrophages predict inferior outcomes in classic Hodgkin lymphoma: a correlative study from the E2496 Intergroup trial
- (2012) K. L. Tan et al. BLOOD
- Metronomic chemotherapy with low-dose cyclophosphamide plus gemcitabine can induce anti-tumor T cell immunity in vivo
- (2012) Miki Tongu et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Constitutive AP-1 Activity and EBV Infection Induce PD-L1 in Hodgkin Lymphomas and Posttransplant Lymphoproliferative Disorders: Implications for Targeted Therapy
- (2012) M. R. Green et al. CLINICAL CANCER RESEARCH
- Metabolism of L-Arginine by Myeloid-Derived Suppressor Cells in Cancer: Mechanisms of T cell suppression and Therapeutic Perspectives
- (2012) Patrick Raber et al. IMMUNOLOGICAL INVESTIGATIONS
- Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2
- (2012) Tadashi Yokosuka et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Selective Effects of PD-1 on Akt and Ras Pathways Regulate Molecular Components of the Cell Cycle and Inhibit T Cell Proliferation
- (2012) N. Patsoukis et al. Science Signaling
- Hallmarks of Cancer: The Next Generation
- (2011) Douglas Hanahan et al. CELL
- Molecular Pathogenesis of Hodgkin's Lymphoma: Increasing Evidence of the Importance of the Microenvironment
- (2011) Christian Steidl et al. JOURNAL OF CLINICAL ONCOLOGY
- Functional characterization of human Cd33+ And Cd11b+ myeloid-derived suppressor cell subsets induced from peripheral blood mononuclear cells co-cultured with a diverse set of human tumor cell lines
- (2011) Melissa G Lechner et al. Journal of Translational Medicine
- Chemokine receptors as therapeutic tools in Hodgkin lymphoma: CCR4 and beyond
- (2010) D. Aldinucci et al. BLOOD
- Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma
- (2010) M. R. Green et al. BLOOD
- DNA Topoisomerases and Their Poisoning by Anticancer and Antibacterial Drugs
- (2010) Yves Pommier et al. CHEMISTRY & BIOLOGY
- Transforming growth factor beta 1 plays an important role in inducing CD4+CD25+forhead box P3+ regulatory T cells by mast cells
- (2010) W. Zhang et al. CLINICAL AND EXPERIMENTAL IMMUNOLOGY
- The classical Hodgkin's lymphoma microenvironment and its role in promoting tumour growth and immune escape
- (2010) Donatella Aldinucci et al. JOURNAL OF PATHOLOGY
- Tumor-Associated Macrophages and Survival in Classic Hodgkin's Lymphoma
- (2010) Christian Steidl et al. NEW ENGLAND JOURNAL OF MEDICINE
- Arginase: an emerging key player in the mammalian immune system
- (2009) Markus Munder BRITISH JOURNAL OF PHARMACOLOGY
- Mechanisms of pre-apoptotic calreticulin exposure in immunogenic cell death
- (2009) Theocharis Panaretakis et al. EMBO JOURNAL
- Gemcitabine directly inhibits myeloid derived suppressor cells in BALB/c mice bearing 4T1 mammary carcinoma and augments expansion of T cells from tumor-bearing mice
- (2009) Hanh K. Le et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- Immunogenic death of colon cancer cells treated with oxaliplatin
- (2009) A Tesniere et al. ONCOGENE
- HLA-G protein expression as a potential immune escape mechanism in classical Hodgkin’s lymphoma
- (2008) A. Diepstra et al. TISSUE ANTIGENS
- Expression of CCR5 receptors on Reed–Sternberg cells and Hodgkin lymphoma cell lines: Involvement of CCL5/Rantes in tumor cell growth and microenvironmental interactions
- (2007) Donatella Aldinucci et al. INTERNATIONAL JOURNAL OF CANCER
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started